Lucia De Franceschi, MD, University of Verona, Verona, Italy, outlines the role of complement activation in sickle cell disease (SCD) complications. Linked to a more severe phenotype, complement activation emerges as a promising therapeutic target currently under evaluation in three ongoing clinical trials. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.